MX2007005427A - Composicion de dispersion solida de pranlukast con biodisponibilidad mejorada y metodo para preparar la dispersion solida. - Google Patents
Composicion de dispersion solida de pranlukast con biodisponibilidad mejorada y metodo para preparar la dispersion solida.Info
- Publication number
- MX2007005427A MX2007005427A MX2007005427A MX2007005427A MX2007005427A MX 2007005427 A MX2007005427 A MX 2007005427A MX 2007005427 A MX2007005427 A MX 2007005427A MX 2007005427 A MX2007005427 A MX 2007005427A MX 2007005427 A MX2007005427 A MX 2007005427A
- Authority
- MX
- Mexico
- Prior art keywords
- pranlukast
- solid dispersion
- clause
- composition
- polymer
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Otolaryngology (AREA)
- Inorganic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020040089455A KR101086254B1 (ko) | 2004-11-04 | 2004-11-04 | 생체이용률이 개선된 프란루카스트 고체분산체 조성물 및그 고체분산체의 제조방법 |
| PCT/KR2005/003686 WO2006049433A1 (en) | 2004-11-04 | 2005-11-03 | Solid dispersion composition of pranlukast with improved bioavailibility and the method of preparing the solid dispersion |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2007005427A true MX2007005427A (es) | 2012-10-02 |
Family
ID=36319405
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2007005427A MX2007005427A (es) | 2004-11-04 | 2005-11-03 | Composicion de dispersion solida de pranlukast con biodisponibilidad mejorada y metodo para preparar la dispersion solida. |
Country Status (6)
| Country | Link |
|---|---|
| JP (1) | JP5232472B2 (enExample) |
| KR (1) | KR101086254B1 (enExample) |
| AR (1) | AR051758A1 (enExample) |
| MX (1) | MX2007005427A (enExample) |
| TW (1) | TWI380829B (enExample) |
| WO (1) | WO2006049433A1 (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101233235B1 (ko) * | 2005-08-26 | 2013-02-15 | 에스케이케미칼주식회사 | 초기 용출율이 개선된 프란루카스트 고체분산체의 약제학적조성물 및 그의 제조방법 |
| EP2187968A4 (en) * | 2007-08-21 | 2013-02-20 | Univ Texas | THERMOKINETIC MIXING FOR PHARMACEUTICAL APPLICATIONS |
| EP4008314A3 (en) * | 2007-08-21 | 2022-11-09 | Board of Regents, The University of Texas System | Thermo-kinetic mixing for pharmaceutical applications |
| EP2140861A1 (en) * | 2008-06-30 | 2010-01-06 | Abbott GmbH & Co. KG | Pharmaceutical dosage form comprising polymeric carrier composition |
| GB201103837D0 (en) * | 2011-03-07 | 2011-04-20 | Oxagen Ltd | Amorphous (5-Fluoro-2-Methyl-3-Quinolin-2-Ylmethyl-Indol-1-Yl)-acetic acid |
| KR101381881B1 (ko) * | 2012-03-12 | 2014-04-04 | 충남대학교산학협력단 | 용해도 및 용출율이 개선된 프란루카스트 나노 고체 분산체의 제조방법 |
| KR101446129B1 (ko) * | 2012-10-10 | 2014-10-06 | 조선대학교산학협력단 | 프란루카스트-함유 고형 제제의 제조방법 |
| KR102191562B1 (ko) * | 2012-11-07 | 2020-12-15 | 에스케이바이오팜 주식회사 | 난용성 약물의 고체분산체 및 이의 제조방법 |
| KR102363727B1 (ko) | 2015-06-01 | 2022-02-16 | 삼아제약 주식회사 | 생체이용률이 개선된 프란루카스트 함유 고형 제제의 조성물 및 그 제조방법 |
| WO2020012498A1 (en) | 2018-07-13 | 2020-01-16 | Council Of Scientific & Industrial Research | Solid dispersion comprising an anticancer compound with improved solubility and efficacy |
| KR20240164596A (ko) | 2023-05-09 | 2024-11-20 | 삼아제약 주식회사 | 복약편의성이 증진된 프란루카스트 함유 약제학적 조성물 |
| KR102840220B1 (ko) | 2023-07-18 | 2025-07-31 | 삼아제약 주식회사 | 프란루카스트 함유 약제학적 조성물의 제조방법 및 상기 제조방법에 의해 제조된 약제학적 조성물 |
| KR20250052834A (ko) | 2023-10-12 | 2025-04-21 | 주식회사 다산제약 | 프란루카스트의 생체이용률이 개선된 약제학적 조성물 및 그 제조방법 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19509807A1 (de) * | 1995-03-21 | 1996-09-26 | Basf Ag | Verfahren zur Herstellung von Wirkstoffzubereitungen in Form einer festen Lösung des Wirkstoffs in einer Polymermatrix sowie mit diesem Verfahren hergestellte Wirkstoffzubereitungen |
| DE69625813T2 (de) * | 1995-06-12 | 2003-09-04 | Ono Pharmaceutical Co. Ltd., Osaka | Pranlukast enthaltende granula, verfahren zur herstellung der granula und verfahren zur verminderung des zusammenbackens von pranlukast |
| US5858509A (en) * | 1996-11-15 | 1999-01-12 | Digital Equipment Corporation | Attenuating vibrations in a mounting shelf for multiple disk drives |
| US6248363B1 (en) | 1999-11-23 | 2001-06-19 | Lipocine, Inc. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
| KR100381834B1 (ko) * | 2000-05-20 | 2003-04-26 | 이상득 | 용출성이 개선된 프란루카스트 고체분산체 조성물 및 그제조 방법 |
| UA80393C2 (uk) | 2000-12-07 | 2007-09-25 | Алтана Фарма Аг | Фармацевтична композиція, яка містить інгібітор фде 4, диспергований в матриці |
-
2004
- 2004-11-04 KR KR1020040089455A patent/KR101086254B1/ko not_active Expired - Lifetime
-
2005
- 2005-11-03 WO PCT/KR2005/003686 patent/WO2006049433A1/en not_active Ceased
- 2005-11-03 JP JP2007540251A patent/JP5232472B2/ja not_active Expired - Fee Related
- 2005-11-03 AR ARP050104618A patent/AR051758A1/es unknown
- 2005-11-03 MX MX2007005427A patent/MX2007005427A/es not_active Application Discontinuation
- 2005-11-04 TW TW094138786A patent/TWI380829B/zh not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| TWI380829B (zh) | 2013-01-01 |
| KR101086254B1 (ko) | 2011-11-24 |
| TW200621307A (en) | 2006-07-01 |
| WO2006049433A1 (en) | 2006-05-11 |
| JP2008519067A (ja) | 2008-06-05 |
| AR051758A1 (es) | 2007-02-07 |
| KR20060040211A (ko) | 2006-05-10 |
| JP5232472B2 (ja) | 2013-07-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2916152B2 (ja) | 薬物放出速度調節型製剤 | |
| CA2292586C (en) | Solid pharmaceutical dosage forms in form of a particulate dispersion | |
| EP1291014B1 (en) | A process for producing a pharmaceutical solid preparation containing a poorly soluble drug | |
| EP0012523B2 (en) | Therapeutic compositions with enhanced bioavailability and process for their preparation | |
| EP2886109B1 (en) | Medicament-containing hollow particle | |
| JP2001511156A (ja) | 高いバイオアベイラビリティーを有するフェノフィブレート医薬組成物及びそれを調製するための方法 | |
| EP3023110B1 (en) | Solution for spray drying comprising hypromellose acetate succinate and method for producing solid dispersion | |
| EP1039909A1 (en) | Method and composition of an oral preparation of itraconazole | |
| WO1997004782A1 (en) | Solid dispersion or solid dispersion preparation of xanthine derivatives | |
| RU2713428C1 (ru) | Частицы, содержащие аморфный эмпаглифлозин, способ их получения и содержащий их лекарственный препарат | |
| JP2002526437A (ja) | アジテーション非依存性薬学的マルチプル−ユニット持効性製剤およびその製法 | |
| MX2007005427A (es) | Composicion de dispersion solida de pranlukast con biodisponibilidad mejorada y metodo para preparar la dispersion solida. | |
| KR20010082250A (ko) | 약물을 함유하는 구형 미립자의 제조 방법 | |
| WO2001089574A1 (en) | Solid dispersion system of pranlukast with improved dissolution, and the preparing method thereof | |
| CN106619520A (zh) | 一种右兰索拉唑钠的干混悬剂及其制备方法 | |
| JP2004525887A (ja) | 新規フェノフィブラート錠剤 | |
| JP5297194B2 (ja) | 初期溶解率が改善されたプランルカスト固体分散体の薬剤学的組成物およびその製造方法 | |
| WO2001085135A1 (en) | PHARMACEUTICAL COMPOSITION CONTAINING ITRACONAZOLE WITH GASTRIC pH-INDEPENDENTLY IMPROVED SOLUBILITY AND PREPARATION METHOD THEREOF | |
| JP2000504309A (ja) | 医薬用顆粒 | |
| JP4754485B2 (ja) | 共沈活性物質含有粒子 | |
| JPS62132830A (ja) | 徐放性医薬品組成物 | |
| KR20110031889A (ko) | 피브레이트계 약물을 포함하는 고체분산체 및 이의 제조방법 | |
| JP2025162521A (ja) | 非晶質固体分散体を含む複合物 | |
| JP2813792B2 (ja) | マレイン酸イルソグラジン経口投与用製剤およびその製造法 | |
| WO2025140579A1 (zh) | 一种药物组合物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |